Ascendis Pharma AS annual net income for fiscal TTM was €753 million, compared with -€219 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | €753M | (€219M) | (€378M) | (€481M) | (€583M) | (€384M) | (€419M) | (€218M) | (€130M) | (€124M) | (€69M) | (€33M) | (€10M) | €4M | €1M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | €207M | €640M | (€33M) | (€61M) | (€39M) | (€95M) | (€38M) | (€99M) | (€109M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ASND metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ASND financial statements → Interactive ASND charts →
About TickerBase · Data methodology & sources · Privacy · Terms